There are 717 resources available
Invited Discussant abstracts 265O, 266O and 267O
Presenter: Ingeborg Tinhofer-Keilholz
Session: Proffered paper and Mini oral mixed session on Head and neck
Resources:
Slides
Webcast
Invited Discussant abstracts 268MO, 269MO and 270MO
Presenter: Edwin Hui
Session: Proffered paper and Mini oral mixed session on Head and neck
Resources:
Slides
Webcast
Invited Discussant abstracts 255O and 256O
Presenter: Lorenz Truemper
Session: Proffered paper session on Haematological malignancies
Resources:
Slides
Webcast
Invited Discussant abstracts 45O and 46O
Presenter: Prudence Francis
Session: Proffered paper session on Breast cancer
Resources:
Slides
Webcast
Invited Discussant abstracts 257O, 258O and 259O
Presenter: Soon Thye Lim
Session: Proffered paper session on Haematological malignancies
Resources:
Slides
Webcast
45O - Abemaciclib plus fulvestrant in East Asian women with HR+, HER2- advanced breast cancer: Overall survival from MONARCH 2
Presenter: Chiun-Sheng Huang
Session: Proffered paper session on Breast cancer
Resources:
Abstract
Slides
Webcast
46O - Neratinib + capecitabine (N+C) vs lapatinib + capecitabine (L+C) in Asians with HER2+ metastatic breast cancer (MBC) previously treated with two or more HER2-directed regimens: A Pan-Asian analysis of the phase III NALA trial
Presenter: Ming Shen Dai
Session: Proffered paper session on Breast cancer
Resources:
Abstract
Slides
Webcast
234O - Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1
Presenter: Michael Friedlander
Session: Proffered paper session on Gynaecological tumours
Resources:
Abstract
Slides
Webcast
235O - Efficacy and safety of Niraparib in Chinese Patients with Platinum-Sensitive Recurrent Ovarian Cancer (NORA) with Individualized Starting Dose: A Subgroup Analysis of A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial
Presenter: Jianqing Zhu
Session: Proffered paper session on Gynaecological tumours
Resources:
Abstract
Slides
Webcast
236O - Olaparib (ola) plus bevacizumab (bev) as maintenance (mx) therapy in patients (pts) with newly diagnosed advanced ovarian carcinoma (OC): Japan subset of the PAOLA-1 trial
Presenter: Keiichi Fujiwara
Session: Proffered paper session on Gynaecological tumours
Resources:
Abstract
Slides
Webcast